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1 Abstract 
Epidermodysplasia Verruciformis (EV) is a human skin disorder characterised by 
widespread verrucous papulosis. EV is associated with a high risk for squamous cell 
carcinoma (SCC) and, aetiologically, with human Papillomaviruses (PVs). Alternatively, 
mutational inactivation of the anti-apoptotic p53 has been linked to SCC pathogenesis. In 
the present work, a dog with EV-like skin lesions was studied. Its predicted p53 sequence 
did not differ from the published sequence of normal dogs, indicating that p53 was not a 
factor in this case. However, a novel canine PV (CPV3) had been discovered in the same 
skin lesions. Now, samples from three different skin lesions of this dog as well as from 
unaffected skin were analyzed for CPV3 E6 mRNA synthesis. Indeed, CPV3 E6 mRNA 
was detected exclusively in the EV-like skin lesions. The putative transforming protein 
CPV3 E6 was expressed, as a fusion protein with the yellow fluorescent protein, from an 
amplicon vector in eukaryotic cells. The fusion protein accumulated in dot-like structures 
within the nucleus of amplicon-transduced cells and, after a few days, caused premature 
cell death. Thus, contrary to expectations, expression of E6 did not increase cell survival, 
which should be a prerequisite for cell transformation. Treatment of cells with a siRNA 
targeting CPV3 E6 did not result in decreased expression of the E6 protein. While CPV3 
seems to be a factor in this case of EV, the underlying molecular mechanisms remain to 
be elucidated.  
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2 Introduction 
2.1 Case presentation 
A seven-year-old Rhodesian Ridgeback was presented at the Dermatology Unit of the 
Clinic for Small Animal Internal Medicine of the University of Zurich, for the evaluation of 
pigmented maculae and nodules and one ulcerated, interdigital plaque. The dog was 
affected by an expanding number of pigmented plaques slowly increasing in size. The first 
lesions were noticed when the dog was six months old. 
Histological examination of the ulcerated plaque revealed marked acanthosis with 
hyperkeratosis and hypergranulosis. The epidermis was disorganized with numerous 
atypical cells, but the basal membrane was intact and the dermis was not affected. A 
diagnosis of squamous cell carcinoma (SCC) in situ was established. 
Topical treatment with the immune response modifier Imiquimod was started, based on 
reports about successful treatment of cutaneous warts1 and invasive SCCs2. Treatment 
did not lead to regression of the lesions. Treatment with omega interferon intralesionally 
and subcutaneously was not successful as well. Consequently, the affected toe had to be 
surgically removed. 
A Papillomavirus (PV) infection was suspected and therefore a polymerase chain reaction 
(PCR) was performed with primers, which are able to amplify conserved regions in PVs. 
PV DNA was detected in different lesions.3 To get more information on the nature of this 
PV, the complete viral genome was cloned. A rolling-circle amplification, which is a 
sequence-independent amplification of circular DNA, was performed.4 After cloning the 
genome, the nucleotide sequence revealed that this PV had not been described before. It 
was named Canine Papillomavirus type 3 (CPV3).5 
 
2.2 Causes of skin cancer 
Skin cancers are primary divided into melanoma and non melanoma skin cancer, whereas 
the latter group includes basal and squamous cell carcinoma. In humans the pathogenesis 
of skin cancer is multifactorial and several causative factors have been reported. The most 
important cause of skin cancer is ultraviolet radiation (UVR).6 It exerts harmful effects to 
the skin through direct cellular damage and alterations in immunologic function. Cellular 
damage occurs due to mutations in DNA, formation of thymidine dimers and alterations in 
p53 tumor suppressor gene. In addition immunodeficiency due to disease or due to 
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administration of immunosuppressive agents substantially increases the risk of skin 
cancer.6 Furthermore viral infections such as the human PV can cause SCC and 
individuals with various familial genetic syndromes, like for example EV or Xeroderma 
pigmentosum, are particularly susceptible to specific types of skin cancer.6 Besides these 
most important causative factors, which can be assumed to be also important factors in 
veterinary medicine, there are many additional risk factors like phototherapy, ionizing 
radiation, chemical carcinogens, aging, tanning, smoking, dermatoses, scars and diet6, 
which most of them seems to be not very likely to play an important role in the 
pathogenesis of skin cancer in animals. 
 
2.3 Epidermodysplasia Verruciformis 
2.3.1 Relevance in humans 
Epidermodysplasia Verruciformis (EV) is a rare inherited skin disease associated with a 
high risk of skin carcinoma that results from an abnormal susceptibility to infection by 
human Papillomaviruses (HPV).7 The disease is characterized by disseminated flat warts 
and macular lesions, which are more or less scaly, red, brown or achromic with irregular 
outlines. The warts develop during early childhood and have, especially on sun exposed 
skin areas, a high risk to turn into SCCs in adults.8 Furthermore an EV - like syndrome has 
been described, which shows clinically clearly parallels with EV, but occurs in patients with 
a severe immune deficiency.9 These patients, in particular organ transplant recipients, 
have also a highly increased incidence of cutaneous SCCs.10 In more than 90 % of the 
SCCs of EV or EV - like patients, DNA sequences specific for oncogenic EV-HPV types 
(predominantly HPV5 and HPV8) could be detected.7 But EV-HPV types also occur at high 
frequency in normal skin of the healthy general population and in patients with benign 
hyperproliferative disorders.11-14 Therefore it is difficult to determine the role of HPVs in the 
skin carcinogenesis.  
UVR is known to be an important etiological agent in the pathogenesis of SCCs.6,15 The 
facts that HPVs also occur in non affected humans and that SCCs occur predominantly at 
body sites exposed to UVR suggests a possible interaction between HPV and UVR in the 
development of SCCs in EV patients.16 This critical dependence on UVR has been further 
supported by the finding of p53 mutations in over 60% of EV SCCs and up to 40 % of pre-
malignant lesions.17,18 Mutations of the p53 gene, which consequently inactivates the p53 
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protein occur in a wide range of human cancers. In skin cancer mutations of the p53 gene 
may be induced by UVR.19 
2.3.2 Relevance in dogs  
Skin lesions similar to human EV were first described in dogs by Briggs et al. and called 
canine lentiginosis profunda.20 Based on its resemblance to verrucous epidermal nevus in 
humans this dermatosis was later designated as pigmented epidermal nevus (PEN).21 
Nagata suggested 1995 that canine PEN is equivalent to EV in humans.22 
Affected dogs have multiple cutaneous macules, papules and plaques of heavily 
pigmented hyperplastic epidermis. Since this disease accumulates in certain dog breeds 
(pug, miniature schnauzer) it is suspected to be an inherited disorder similar to the human 
EV.20,22,23 Moreover, two case reports lead to the assumption that an EV-like syndrome 
associated with immunsuppression occurs also in dogs: Callan et al. referred 2005 to a 
dog, which developed multiple epidermal harmatomas and SCCs in situ following chronic 
immunosuppressive therapy.24 And Stokking et al. reported 2004 on three dogs with 
pigmented epidermal plaques, whereas two cases had a concurrent disease associated 
with impaired immune function.25 Furthermore many publications about PV detection in 
such skin lesions indicate an involvement of PV in the development of the disease in 
dogs22-26 and the possibility of malignant transformation of the lesions into SCC is 
suggested.22,25 
 
2.4 p53  
p53 is the most commonly mutated gene in human cancers.27 It encodes a 53 kilodalton 
protein, which consists of several functional domains with specific properties. The 
transactivation domain is located in the N-terminal part of the protein. Sequence-specific 
DNA binding is mediated through the central core and the C-terminal part of p53 is 
composed of a flexible linker region, an oligomerization domain and a basic, regulatory C-
terminal region.27 In unstressed cells, p53 is present in a latent state and is maintained at 
low levels through targeted degradation.28 In response to various stress signals, such as 
oncogene activation, UVR, hypoxia, virus infection and DNA damage, p53 accumulates in 
the nucleus and is activated as a transcription factor.28 Activation of p53 induces or inhibits 
the expression of more than 150 genes, leading either to cell cycle arrest in the G1/S or 
G2/M phases or to apoptosis.28 Normally, the p53 protein interacts with the Mdm2 protein, 
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which targets p53 for ubiquitin-mediated degradation, whereas Mdm2 is induced by p53, 
creating an autoregulatory loop.27 Phosphorylation at the N-terminus reduces p53 
interaction with Mdm2 with a resultant increase in p53 protein level.27 Modification at the 
C- and N-termini via phosphorylation or acetylation upregulates binding to specific DNA 
targets increasing transcription of downstream genes, which induce cell cycle arrest, 
allowing time for repair of the occurred damage, or apoptosis, if the DNA damage proves 
to be irrepairable.29 Loss of this protective function occurs as a consequence of p53 gene 
mutation, which results in a functionally impaired protein or as a consequence of p53 
protein inactivation due to viral proteins such as high risk HPV E6.29 This loss of p53 
response plays an important role in tumorigenesis.27,29  
 
2.5 Papillomaviruses 
2.5.1 General properties 
Papillomaviruses (PVs) induce warts in a variety of higher vertebrates. They are highly 
species specific and have a specific tropism for cutaneous or mucosal squamous epithelial 
cells.30 
2.5.2 Structure and organization 
The papillomavirus capsids are nonenveloped icosahedral particles about 55 nm in 
diameter. The viral genome consists of a single molecule of double-stranded circular DNA 
about 8 kilo base pairs (bp) in size.30 About ten open reading frames (ORFs) are located 
on one strand of the viral DNA. These ORFs are classified as either early (E) or late (L) 
ORFs, based on the time of expression during infection. The E and L genes are well 
separated on the genome both regions ending with a poly-adenylation signal. The early 
region of the PV genome encodes viral proteins involved in the regulation of replication 
and the synthesis of viral DNA. The L1 and L2 ORFs encode the two structural capsid 
proteins and are expressed only in productively infected cells. Furthermore the PV 
genome contains a region without ORFs called long control region (LCR). This noncoding 
region varies slightly in size among the different PVs.30 
 6 
2.5.3 Life cycle 
The following general concept about the HPV life cycle appears to be applicable to the 
animal PVs that are already studied. Life cycle of HPVs is tightly connected to the 
differentiation of epithelial cells and depends on infection of dividing cells.31 Basal cells in 
squamous epithelium can be reached by the virus due to a micro trauma in the skin. After 
infection, viral DNA is transported into the nucleus and genome is maintained as an 
episome due to expression of E1 and E2 proteins. Infected basal cells migrate towards the 
epithelial surface. Normally basal cells exit the cell cycle after migrating into the 
suprabasal cell layers and undergo a process of terminal differentiation. However this 
terminal differentiation is retarded by E6 and E7 proteins of PVs and the cells are kept in 
the proliferative phase.31 E6 and E7 are thought to work together to achieve these effects. 
Whereas E7 stimulates S-phase progression and results in unscheduled S-phases, E6 
prevents the induction of apoptosis, which in turn increases the chance of mutations and 
consequently is a predisposing factor in the development of cancer.31 Genome 
amplification and packaging into infectious particles occurs in the mid or upper epithelial 
layers and depends of the co-expression of all viral gene products. Once viral genome 
amplification has been completed virus synthesis is performed in the upper layers of 
infected tissue by expression of the two structural proteins L1 and L2. Throughout the virus 
life cycle, levels of different viral proteins are controlled by promotor usage and by different 
splice site selection.31 
2.5.4 Relevance in humans 
A number of human papillomaviruses (HPVs) have been implicated as the etiologic agent 
for cervical cancer and other epithelial tumors.30 To date, nearly hundred different HPV 
types have been identified based on the characterization of complete genomes, with a yet 
larger number presumed to exist based on the detection subgenomic amplicons.32 The 
association of certain HPV types with benign and malignant lesions has led to the 
definition of «high-risk» types, «intermediate-risk» types and «low-risk» types.33 About 25 
HPV types preferentially infect the anogenital mucosa. In addition to their role in anogenital 
cancer, HPVs are also involved in the development of cutaneous lesions. These are 
commonly referred to as EV-HPV types and include HPV5, 8, 9, 12, 14, 15, 17, 19-25, 36-
38, 47 and 49.34 
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2.5.5 HPV E6 and E7 proteins 
The HPV E6 proteins are small polypeptides of approximately 150 amino acids and 
contain two CX2CX29CX2C motifs, which are believed to be involved in binding zinc. The 
E7 protein encoded by the HPVs consists of about 100 amino acids and also contains 
such a zinc binding motif.30 Both proteins are consistently expressed in HPV-carrying 
anogenital malignant tumors and are able to immortalize a wide variety of human cell 
types cooperatively.35 In case of high risk anogenital HPV types, the viral transforming 
genes E6 and E7 are therefore thought to be responsible for the development of cancer.36 
The E6 protein initiates degradation of the cellular tumor suppressor protein p53 via an 
ubiquitin-mediated pathway.37 The p53 protein plays a key role in cellular responses to 
stress factors, such as DNA damage or hypoxia, principally through an induction of cell 
cycle arrest or apoptosis.38 Furthermore the E6 protein targets a variety of other host-cell 
proteins, for example it mediates the degradation of the pro-apoptotic protein, Bak, a 
member of the Bcl-2 family.35 Similar to E6, the E7 protein functions are also pleiotropic. 
Amongst others, it binds to the cellular tumor suppressor protein pRB and to the 
retinoblastoma protein-related pocket proteins, what results in enhanced degradation of 
these proteins.35,39 
In contrast to high risk anogenital HPV types, the E6 protein of EV HPV types is unable to 
promote p53 degradation.40,41,42 But E6 proteins of different cutaneous HPVs have been 
shown to inhibit p53-dependent and p53-independent apoptotic pathways in response to 
UVR damage.16 Jackson et al. showed 2000 that the expression of the pro-apoptotic 
protein Bak increases in human kerationcytes treated with UVR, but not in cell lines 
expressing the cutaneous HPV E6 proteins. They suggested that E6 proteins of cutaneous 
HPVs promote proteolytic degradation of Bak and that this elimination of Bak protein leads 
to a decrease in apoptosis in UV-irradiated cells.43 
2.5.6 Relevance in dogs 
To date only canine oral PV (COPV) has been studied extensively. It induces benign 
papillomas in the mucous membrane of the oral cavity of dogs. The nature and the 
biological properties of the remaining canine PVs is largely unknown. Recently Zaugg et 
al. reported the detection of novel PVs in canine SCCs and suggested that those PV 
contribute to the development of malignancy and that the differentiation between low and 
high risk canine PV is feasible.3 
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2.5.7 Canine Papillomavirus 3 
The CPV3 genome counts 7801 bp and has a typical PV genome structure with an early 
region (E1, E2, E6, and E7), a late region (L1, L2) and a non-coding LCR between the end 
of L1 and the beginning of E6.5 The genomic map of CPV3 DNA is shown in Figure 1. The 
size and the content of CX2CX29CX2C motifs of CPV3 E6 and E7 proteins are similar to 
HPV E6 and E7 proteins. The sequence of CPV3 is 56% and 55% identical to COPV or 
CPV2 on the nucleotide level.5 Unlike COPV, whose genome contains a large non coding 
sequence between the E2 and L2 ORF (1500 bp), the CPV3 gap between these two ORFs 
is only 211 bp. Phylogenetic analysis, based on the nucleotide sequence coding for the L1 
protein, does not group CPV3 into one of the defined PV genera.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: CPV3 genomic map. The numbers show the nucleotide positions of the ORFs. 
 
 
2.6 Herpesvirus amplicon system 
Spaete and Frenkel detected 1982 that an origin of DNA replication (ori) and a packaging 
signal (pac) are the only two cis-acting sequences required for replication and packaging 
of defective virus genomes in the presence of a trans-acting herpes simplex virus-1 (HSV-
1) helper-virus.44 This primary observation was adapted to develop the HSV-1 amplicon 
system. The amplicon system is a versatile vector for heterologous expression of genes in 
CPV3
7801 bp
E1 (732-2615)
E2 (2560-4008)
L2 (4219-5733)
L1 (5757-7256)
E6 (25-477)
E7 (425-739)
 
 9 
vitro and in vivo. An amplicon vector containing a transgene cassette with the gene of 
interest, sequence elements of HSV-1, including an ori- and a pac-signal is cotransfected 
together with a cloned HSV-1 helper virus genome lacking the pac-signal into permissive 
cells. This results in virions filled with amplicon DNA which can subsequently be used for 
transduction of cells in order to express the gene of interest.44 Heterologous expression of 
genes using the amplicon system has two main advantages over the transfection of 
plasmid DNA. First, the expression is tunable in a sense that the more amplicons are 
applied to cells the more cells express the gene of interest and second, transduction is 
better tolerated by cells than transfection with lipid/DNA complexes.44 
 
2.7 RNA interference 
RNA interference is a sequence specific, posttranscriptional gene silencing mechanism, 
which is triggered by small interfering, double-stranded (ds) RNA (siRNA) and causes 
degradation of mRNA homologous in sequence to the siRNA.45 siRNAs consist of about 
21 nucleotides and are naturally produced as a part of the RNA interference pathway, 
which has been shown to knock down a large number of genes expressed in mammalian 
cells.45 siRNAs are generated when long ds RNAs are recognized and digested by an 
RNAse-like enzyme called Dicer. Afterwards they are incorporated into a multicomponent 
nuclease called RISC (RNA induced silencing complex) that mediates unwinding of the 
siRNA duplex and targeting of mRNA. This binding mediates target mRNA to be cleaved 
by Dicer. The cleaved mRNA can be recognized by the cells as being aberrant and be 
destroyed.45 The process of RNA interference is self-replicative, while siRNAs 
simultaneous serve as primers to transform the target mRNA into more ds siRNA 
molecules.46 Such siRNA targetting specific mRNA can exogenously introduced for 
specific inhibition of gene expression.47,48 Butz et al. showed 2003 that siRNAs directed 
against HPV E6 provide very efficient molecular tools to inhibit intracellular E6 activities 
specifically.49 
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2.8 Aim of the study 
The aim of this study was to further analyse the role of CPV3 in the development of the 
skin lesions of the affected Rhodesian Ridgeback. Other causative factors in the 
pathogenesis of SCCs have been investigated and were excluded. No evidence of 
immunosupression was found in the history of the dog. A congenital disorder was not 
suspected since no relatives of the dog showed a similar skin disease. However there is 
no possibility to exclude this option. The possibility of an UVR induced mutation of the p53 
gene was eliminated by determination of the mRNA nucleotide sequence of this gene. No 
other causative factor for the SCC development could be identified. Thus the CPV3 
infection became more important. Therefore, our next step was to determine viral gene 
expression by evaluating the presence of CPV3-E6 mRNA in skin lesions of the affected 
dog. Detection of CPV3-E6 mRNA in three different skin lesions, but not in healthy skin, 
underlined the importance of the CPV3 infection in skin cancerogenesis. To further 
evaluate the involvement of PVs in the development of skin lesions, it was necessary to 
investigate the role of the putative transforming proteins E6 and E7, which may be crucial 
for cancerogenesis. Therefore the next step was to characterize the CPV3 E6 protein in 
two ways: First, by observation of the expression and localization of the CPV3-E6 protein 
in eukaryotic cells. And second, by examination of the effects of a siRNA targeting E6 on 
the expression of CPV3 E6 in cell cultures. 
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3 Material and Methods 
3.1 Sample Collection 
Skin samples were taken whilst the dog was conscious. 0,5ml of 1% Lidocain was 
infiltrated into the subcutis under the sites marked for biopsy. One non-lesional and one 
lesional sample was taken from the abdomen. The other two lesional samples were taken 
from the thorax. Six-millimetre diameter skin biopsies were taken, cut into two pieces, 
placed immediately into liquid nitrogen and then stored at –80°C. 
 
3.2 Plasmids 
3.2.1 pTOPO-p53 
pTOPO-p53 was constructed by using the TOPO TA Cloning Kit (Invitrogen, Basel, 
Switzerland). For amplification of the p53 transcripts of the affected dog RNA of healthy 
skin and of lesion 3 was extracted, reverse transcribed as described below (3.3.1) and 
subsequently amplified by using the p53+2 and p53neu- primers (Table 1). PCR reaction 
was performed in the thermocycler PTC 200. The following reagents were added in a 
200µl PCR-reaction tube: 1µl dNTP (10mM), 2µl of each primer (10µM), 5µl cDNA, 10µl 
5X Phusion High-Fidelity buffer and 0,5µl (1unit) Phusion High-Fidelity DNA-Polymerase 
(Finnzymes, Espoo, Finland). The mix was topped up to 50µl with ddH2O. PCR conditions 
involved an initial denaturation step at 98°C for 2 min, followed by 35 cycles consisting of a 
denaturation step at 98°C for 10sec, an annealing s tep at 52°C for 30sec and an extension 
step at 72°C for 45sec, and by a final extension st ep at 72°C for 10min. The PCR product 
was run through an agarose gel and cleaned by using the QIAEX II Agarose Gel 
Extraction Kit (Qiagen, Basel, Switzerland). 20µl of the eluted DNA were incubated with 
0,1µl Taq DNA Polymerase and 1µl 10 mM dATP`s for 15min at 72°C to create 3´ 
overhanging As and cloned into the pCR 2.1-TOPO vector according the manufacturers 
instructions (Invitrogen Basel, Switzerland). In brief, the cloning reaction consisted of 4µl 
PCR product, 10ng vector and 1µl salt solution. The reaction was gently mixed and 
incubated on ice for 5min. Afterwards, 2µl of the reaction were transformed into chemically 
competent TOP 10 E.coli (Invitrogen, Basel, Switzerland) and plated onto LB-Agar plates 
containing 100µg/ml ampicillin. Colonies were expanded over night at 37°C in LB 
supplemented with 100µg/ml ampicillin and plasmid DNA was extracted with the Sigma 
 12 
GenElute™ HP Plasmid Purification Kit (Sigma-Aldrich Corporation, Switzerland, Buchs). 
The sequences were determined by Microsynth AG Sequencing Group (Balgach, 
Switzerland).  
3.2.2 pHSV-E6-EYFP 
To construct a Herpesvirus amplicon vector the Gateway technology (Invitrogen, Basel, 
Switzerland) was used. A coding region of CPV3 E6 was obtained by PCR amplification of 
pCPV3 with the appropriate primers (E6++ and E6-, Table 1). PCR reaction was 
performed in the thermocycler PTC 200. The following reagents were added in a 200µl 
PCR-reaction tube: 2µl dNTP (10mM), 2,5µl of each primer (10µM), 1µl plasmid DNA 
(provided by the Institute of Virology, Zurich, Switzerland), 5µl 10X Pfu reaction buffer and 
1µl (2,5units) PfuTurbo DNA polymerase (Stratagene, Amsterdam, The Netherlands). The 
mix was topped up to 50µl with ddH2O. PCR conditions involved an initial denaturation 
step at 95°C for 2min, followed by 35 cycles consis ting of a denaturation step at 95°C for 
1min, an annealing step at 47°C for 1min and an ext ension step at 72°C for 1min, and by a 
final extension step at 72°C for 10min. The PCR pro duct was cleaned by using the QIAEX 
II Agarose Gel Extraction Kit (Qiagen, Basel, Switzerland) and directionally cloned into the 
pENTR/D-TOPO vector. The CACC sequence at the 5`end of the forward primer paired 
with the overhang sequence GTGG in the pENTR/D-TOPO vector and enabled the 
directional cloning of the blunt end PCR products into an entry clone. The cloning reaction 
consisted of 23.2ng PCR product, 20ng TOPO vector, 1µl salt solution and water added to 
a final volume of 6µl. The reaction was gently mixed and incubated for 5min at room 
temperature (RT). Afterwards, 2µl of the reaction were transformed into competent TOP 10 
E.coli (Invitrogen, Basel, Switzerland) and plated onto LB-Agar plates containing 50µg/ml 
kanamycin. After sequencing of the resulting clone (pENTR-E6) the LR recombination 
reaction between this entry clone and the destination vector pHSV-EYFP-RfC (provided by 
the Institute of Virology, Zurich, Switzerland) was performed. The recombination reaction 
consisted of 254ng entry clone, 425ng destination vector, 4µl 5x LR clonase buffer and TE 
buffer pH 8.0 added to a final volume of 16µl. After gently mixing the reaction, 4µl of LR 
Clonase enzyme mix were added, the reaction mix was mixed well and incubated at 25°C 
for 1 hour. After adding of 2µl of Proteinase K solution the reaction mix was incubated for 
10min at 37°C. 1µl of the recombination reaction wa s transformed into competent TOP 10 
E.coli (Invitrogen, Basel, Switzerland) and plated onto LB-Agar plates containing 100µg/ml 
ampicillin. For purification of plasmid DNA the Sigma GenElute™ HP Plasmid Purification 
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Kit (Sigma-Aldrich Corporation, Switzerland, Buchs) was used. Clones were checked by 
restriction enzyme analysis and sequence analysis was done by Microsynth AG 
Sequencing Group (Balgach, Switzerland).  
3.2.3 pTOPO-GAPDH 
pTOPO-GAPDH was constructed by using the TOPO TA Cloning Kit (Invitrogen, Basel, 
Switzerland). For amplification of canine GAPDH RNA of canine skin was extracted and 
reverse transcribed as described later (3.3.1) and subsequently amplified by using the 
GAPDH2+ and GAPDH2- primers (Table 1). PCR conditions involved an initial 
denaturation step at 94°C for 3min, followed by 35 cycles consisting of a denaturation step 
at 94°C for 30sec, an annealing step at 55°C for 30 sec and an extension step at 72°C for 
30sec, and by a final extension step at 72°C for 5m in. The PCR product was run through 
an agarose gel and cleaned by using the QIAEX II Agarose Gel Extraction Kit (Qiagen, 
Basel, Switzerland) and directionally cloned into the pCR 2.1-TOPO vector. The cloning 
reaction consisted of 82ng PCR product, 10ng vector, 1µl salt solution and water added to 
a final volume of 6µl. The reaction was gently mixed and incubated on ice for 5min. 
Afterwards, 2µl of the reaction were transformed into competent TOP 10 E.coli (Invitrogen, 
Basel, Switzerland) and plated onto LB-Agar plates containing 25µg/ml kanamycin. 
Plasmid DNA purification was done with the Sigma GenElute™ HP Plasmid Purification Kit 
(Sigma-Aldrich Corporation, Switzerland, Buchs) and sequence analysis (Microsynth AG 
Sequencing Group, Balgach, Switzerland) confirmed that pTOPO-GAPDH contained the 
desired GAPDH insert.  
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Primer Target Method Term Sequence 
CPV3-E6 PCR E6++ 5`-CACCATGGAGCGTCCATGGAGC-3` 
CPV3-E6 PCR E6- 5`-AGAACGATGTCTCTCAAAGTAGCG-3` 
CPV3-E6 Real Time PCR TaqE6+ 5`-TCCAAGCACTCTACAGAAGACAG-3` 
CPV3-E6 Real Time PCR 
PCR 
TaqE6- 5`-AGCGTCTTTCCCAATCATTATCAG-3` 
Canine GAPDH and  
Real Time PCR 
GAPDH2+ 5`-CGGCATCGTGGAGGGCCTCATGAC-3` 
Canine GAPDH PCR and  
Real Time PCR 
GAPDH2- 5`-ATGCCAGTGAGCTTCCCGTTCAGC-3` 
Canine p53 Reverse 
Transcription 
p53- 5`-TTAACCTCAGTCTGAGTCAAGCCCT-3` 
Canine p53 PCR p53+2 5`-ATGCAAGAGCCACAGTCAGAGCTC-3` 
Canine p53 PCR p53neu- 5`-GATTGCCCCTTCTTTGCCTTCA-3` 
 
Table 1: Primers for amplification of CPV3 E6, canine GAPDH and canine p53 
 
3.2.4 pHSV-E6-mRFP 
To replace the yellow fluorescent protein gene of pHSV-E6-EYFP with the red fluorescent 
protein gene of pcDNA-mRFP1-N (provided by the Institute of Virology, Zurich, 
Switzerland), the plasmid DNAs were digested with Asp718 and EcoRI and subsequently 
analysed on agarose gel. The desired DNA fragments were cleaned using the QIAEX II 
Agarose Gel Extraction Kit (Qiagen, Basel, Switzerland) and ligated. The ligation reaction 
mix consisted of 120ng of linearized pHSV-E6, 55ng of excised mRFP, 1.2µl ligase buffer, 
1µl ligase and 4.3µl water and was incubated at 25°C for 30min. Afterwards, 4µl of the 
ligation reaction were transformed into competent TOP 10 E.coli (Invitrogen, Basel, 
Switzerland) and plated onto LB-Agar plates containing 100µg/ml ampicillin.  
3.2.5 pHSVsiE6 
Amplicon vector pHSVsuper (provided by the Institute of Virology, Zurich, Switzerland) 
contains an HSV-1 origin of DNA replication (OriS), a HSV-1 DNA packaging signal (Pac), 
EGFP under control of the HSV-1 IE 4/5 promotor, a RNA polymerase III-dependent H1 
promotor and a well-defined start of transcription and a termination signal. This vector was 
digested with BglII and HindIII, analysed on agarose gel and the desired DNA fragment 
was cleaned using the QIAEX II Agarose Gel Extraction Kit (Qiagen, Basel, Switzerland). 
DNA oligonucleotides targeting CPV3 E6 at two different locations (Table 2) were 
synthesized (Microsynth, Balgach, Switzerland) as 64-mer sense and antisense 
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oligonucleotide templates (2 x 19 nucleotides specific to the targeted sequences and 26 
nucleotides for restriction enzyme recognition sites and hairpin structure) as described 
previously.58 These oligonucleotides were annealed and ligated with the linearized 
pHSVsuper. The annealing reaction mix consisted of each 3µg sense and antisense 
oligonucleotide template and 48µl annealing buffer (50mM HEPES pH 7.4, 25 mM NaCl) 
and was incubated at 95°C for 5min, at 70°C for 10m in and then slowly cooled down to 
4°C. The ligation reaction mix consisted of 2µl of the annealed oligonucleotides, 2µl of 
digested pHSVsuper, 1µl ligase buffer, 1µl ligase and 4µl water and was incubated at 14°C 
over night (o/n). Afterwards, 2µl of the ligation reaction were transformed into MAX 
Efficiency DH10BTM competent cells (Invitrogen, Basel, Switzerland) and plated onto LB-
Agar plates containing 100µg/ml ampicillin. The resulting amplicons were designated 
pHSVsiE6-2 and pHSVsiE6-3.  
 
siRNA Target nt Sequence 
CPV3 E6-2 4035-4053 AGAGAGGTGTCACAGTACA 
CPV3 E6-3 5013-5031 ATACCAGTGAGGTGCACAT 
 
Table 2: siRNA target sequences within the CPV3 E6 ORF 
 
3.3 Real time PCR 
3.3.1 RNA Extraction and Reverse Transcription 
Total RNA was extracted from the skin biopsies by using the RNeasy Mini Kit with RNase-
Free DNase Set (Qiagen, Basel, Switzerland) according to the manufacturer's instructions. 
The extracted RNA was eluted in 40µl RNase free water and divided into 5 aliquots. Each 
aliquot of RNA was again treated with 1µl DNase (Promega, Madison, WI) to degrade the 
residual DNA. After an incubation of 30min at 37°C,  1µl DNase Stop solution was added 
and the reaction was incubated at 75°C to destroy D Nase. Reverse transcription was done 
with the Reverse Transcription System (Promega, Madison, WI) by using oligo dT primer 
to reverse transcribe mRNA. The reverse transcription reaction contained 4µl MgCl, 2µl 
RT buffer, 2µl dNTPs, 0.5µl RNasin, 1µl Oligo dT primer, 0.75µl reverse transcriptase and 
one aliquot of RNA. As a negative control another aliquot of RNA was mixed in exactly the 
same way but instead of 0.75µl reverse transcriptase 0.75µl water was added (=no-RT 
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mRNA sample). For the generation of p53 cDNA 1µl of a 10µM gene-specific reverse 
primer (p53-) was used instead of the Oligo dT primer. 
3.3.2 Quantitative PCR analysis of skin samples 
Real-time quantitative PCR was performed in single wells of a 96-well plate in a 25µl 
reaction volume using the iCycler IQTM (Bio-Rad, Hercules, CA). The 25µl reaction mixture 
contained 12.5µl IQTM SYBR Green Supermix (2X) (Bio-Rad, Hercules, CA), 5pmol of 
forward and reverse primer, 10µl of different dilutions of cDNA and water was added up to 
25µl. The used primers are listed in Table 1 (TaqE6+, TaqE6-, GAPDH2+ and GAPDH2-). 
Reactions were amplified in duplicate and incubated according to the iCycler 
2StepAmp+Melt.tmo protocol (BioRad, Hercules, CA). The corresponding no-RT mRNA 
sample was included as a negative control and one sample consisting of distilled water 
was amplified to control contamination. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as a reference gene. Data were analyzed with the iCycler iQ Real-
Time PCR Detection System Software, version 3.1, Biorad. The conditions for the 
determination of the Ct-values were standardised as follows: baseline cycles were defined 
from cycle 2 through cycle 19 and the threshold position was placed at 50 fluorescent 
units. Samples were considered negative if the Ct values exceeded 40 cycles. 
 
3.4 Cells 
VERO cells and VERO 2-2 cells were maintained in Dulbecco`s modified Eagle medium 
(DMEM) (Gibco BRL, Life Technologies, Basel, Switzerland) supplemented with 2%, 6% 
or 10% fetal calf serum (FCS) (AMIMED, BioConcept, Allschwil, Switzerland), 100 units/ 
ml Penicillin G (Sigma, Buchs, Switzerland) and 75 units/ ml Streptomycin (Sigma, Buchs, 
Switzerland) in a humidified 5% CO2 incubator at 37°C. To prevent contamination, all w ork 
was done in the laminar flow. Pictures of the cells were taken using an inverse microscope 
Zeiss Axiovert S100 with or without appropriate UV-filter. 
3.4.1 Transfection of VERO cells with pHSV-E6-EYFP 
For transfection of VERO cells with the pHSV-E6-EYFP amplicon vector a 6 well plate 
containing 4x105 VERO cells per well was incubated o/n. For each dish, 100µl OptiMEM 
were mixed with 1.6µg pHSV-E6-EYFP DNA. In a second tube 100µl OptiMEM were 
mixed with 4µl LipofectAMINE (Invitrogen, Basel, Switzerland). Both tubes were incubated 
 17 
for 5min at RT. After gently mixing both tubes, the content of the tubes were combined, 
mixed and incubated for 20min at RT. Afterwards 1ml OptiMEM was added and the 
transfection mix was applied to the cells which were then incubated for 5 hours at 37°C. 
Thereafter, the transfection mix was aspirated from the cells and they were washed with 
DMEM (0% FCS). Finally, 2ml DMEM (2% FCS) were added and the cells were incubated 
for 48 hours. To visualize the nuclei cells were stained with 0.01µg/ ml Hoechst 33342 
(Invitrogen, Basel, Switzerland). 
3.4.2 Packaging of pHSV-E6-EYFP into HSV-1 particles  
For packaging of pHSV-E6-EYFP into HSV-1 particles 4 x 6cm2 tissue culture dishes 
containing 1.2x106 VERO 2-2 cells were incubated over night. For each dish, 250µl 
OptiMEM were mixed with 2µg fHSV∆pac∆27 DNA, 0.2µg pEBHICP27 DNA and 0.4µg 
pHSV-E6-EYFP DNA. After overlaying with 10µl Plus reagent the reaction mix was 
incubated for 10min at RT. Thereafter it was carefully mixed and incubated for another 
5min at RT. In a second tube 250µl OptiMEM were mixed with 16µl LipofectAMINE 
(Invitrogen, Basel, Switzerland) and incubated for 5min at RT. After gently mixing of both 
tubes, the content of the tubes were combined and incubated for 30min at RT. Afterwards 
900µl OptiMEM were added and the transfection mix was applied to the cells which were 
incubated for 4 hours at 37°C. Thereafter, the tran sfection mix was aspirated from the cells 
and they were washed with OptiMEM. Finally 3.5ml DMEM (6% FCS) were added and the 
cells were incubated for three days. To harvest the amplicon particles the VERO 2-2 were 
scraped into the medium 3 days post co-transfection. The cell suspension was sonicated 
on ice for 20sec with 20% output energy and the cell debris was removed by 
centrifugation. The supernatant was divided into aliquots and these were frozen in an 
ethanol-dry ice bath. The frozen aliquots were stored at –70°C. 
3.4.3 Transduction of VERO/ VERO 2-2 cells with pHSV-E6-EYFP amplicon 
particles 
For transduction of VERO/ VERO 2-2 cells with pHSV-E6-EYFP amplicon particles a 12 
well plate containing 1,8x105 cells per well was incubated over night. Next day 200µl of the 
amplicon particles were added to the cells. After incubation for four hours the cells were 
washed with PBS, 1ml DMEM (2% FCS) was added and the cells were incubated for 24 
hours. 
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3.4.4 Packaging of pHSVsiE6-2, pHSVsiE6-3, pHSVsiEGFP and pHSVsuper 
into HSV-1 particles 
For packaging of the siRNAs pHSVsiE6-2 and pHSVsiE6-3 and the controls pHSVsiEGFP 
and pHSVsuper (provided by the Institute of Virology, Zurich, Switzerland) into HSV-1 
particles 6 x 6cm2 tissue culture dishes containing 1.2x106 VERO 2-2 cells were incubated 
over night. For each dish, 250µl OptiMEM were mixed with 2µg fHSV∆pac∆27 DNA, 0.2µg 
pEBHICP27 DNA and 0.4µg pHSV-E6-EYFP DNA. After overlaying with 10µl Plus reagent 
the reaction mix was incubated for 10min at RT. Thereafter it was carefully mixed and 
incubated for another 5min at RT. In a second tube 250µl OptiMEM were mixed with 16µl 
LipofectAMINE (Invitrogen, Basel, Switzerland) and incubated for 5min at RT. After gently 
mixing of both tubes, the content of the tubes were combined and incubated for 30min at 
RT. Afterwards 900µl OptiMEM were added and the transfection mix was applied to the 
cells which were incubated for 4 hours at 37°C. The reafter, the transfection mix was 
aspirated from the cells and they were washed with OptiMEM. Finally 3.5ml DMEM (6% 
FCS) were added and the cells were incubated for three days. To harvest the infectious 
amplicon particles the VERO 2-2 were scraped into the medium 3 days post co-
transfection. The cell suspension was sonicated on ice for 20sec with 20% output energy 
and the cell debris were removed by centrifugation. The supernatant was purified and 
concentrated using a sucrose gradient. Afterwards the amplicon particles were 
resuspended o/n in 280µl HBSS at 4°C. On the next d ay, the amplicon-HBSS mix was 
gently mixed, divided into aliquots, which were frozen in an ethanol-dry ice bath. The 
frozen aliquots were stored at –70°C. Titration was  done by counting the number of green 
cells 24 h following infection of VERO 2-2 cells using a fluorescence microscope. 
3.4.5 Transduction of VERO 2-2 cells with siRNA amplicon particles and 
control amplicon particles 
For transduction of VERO 2-2 cells with pHSVsiE6-3, pHSVsiEGFP and pHSVsuper 
amplicon particles a 24 well plate containing 5x104 cells per well was incubated o/n. Next 
day 1x105 transducing units (TU) were mixed with 250µl DMEM (2% FCS) and added to 
the cells. After incubation for four hours the cells were washed with PBS, 0.5ml DMEM 
(2% FCS) was added and the cells were incubated for 24 hours. 
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3.4.6 Transfection of VERO 2-2 cells with pHSVE6-mRFP 
To transfect the transduced VERO 2-2 cells with pHSV-E6-mRFP, for each well 25µl 
OptiMEM, 0.25µg pHSV-E6-mRFP DNA and 4µl PLUS reagent (Invitrogen, Basel, 
Switzerland) were mixed and incubated at RT for 15min. In a second tube 25µl OptiMEM 
were mixed with 1µl LipofectAMINE (Invitrogen, Basel, Switzerland). After gently mixing 
both tubes, the content of the tubes were combined, mixed and incubated for 15min at RT. 
Afterwards 250µl OptiMEM was applied and the transfection mix was added to the cells 
which were incubated for 4 hours at 37°C. Thereafte r, the transfection mix was aspirated 
from the cells and they were washed with DMEM (0% FCS). Finally, 0.5ml DMEM (2% 
FCS) was added and the cells were incubated for 24 hours. 
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4 Results 
4.1 Sequencing of p53 
In order to include or exclude a p53 gene mutation as a causative factor in the 
development of skin lesions, RNA of healthy skin and of lesion 3 was extracted, reverse 
transcribed with a gene specific reverse primer, amplified by PCR and cloned into pCR 
2.1-TOPO as described in Material and Methods. Agarose gel electrophoresis of the PCR 
products revealed a band of the expected size (1091 bp) corresponding to a large 
fragment of the p53 ORF (Figure 5). The isolated and purified PCR products were used for 
the TOPO cloning reaction. Whereas the resulting plasmid pTOPO-p53_1 contained the 
p53 molecule of the healthy skin and plasmid pTOPO-p53_2 contained the p53 molecule 
of lesion 3. To identify clones containing the desired piece of DNA, ten colonies of each 
construct were selected, plasmid DNA prepared and restriction analysis with two restriction 
enzymes (SacI and EcoRI) was performed. For both constructs six of the ten isolated 
clones showed the expected restriction pattern. To analyze the p53 sequence, two clones 
of each construct showing the calculated restriction pattern were sequenced (pTOPO-
p53_1D, pTOPO-p53_1F, pTOPO-p53_2C and pTOPO-p53_2G). Sequence analysis 
revealed that the inserted p53 molecule of every analysed clone contained the same 
nucleotide sequence. Setoguchi et al. reported 2001 about the canine wild type p53 
sequence, consisting of 1247 bp, which contained the 5´noncoding region (46 bp), the 
ORF (1146 bp) and the 3`noncoding region (55 bp). Comparison of our 1091 bp long 
sequence (covering nearly the entire p53 ORF) with the 1247 bp long wild type revealed, 
that these 1091 bases were completely identical.50 The shortening of the cloned p53 
fragment resulted from the method used to obtain the amplified cDNA (reverse 
transcription with specific primer followed by PCR with a nested reverse primer). Primers 
for PCR amplification reached from nucleotide 47 to 70 and from nucleotide 1137 to 1116. 
Therefore we effectively analysed 1045 nucleotides, corresponding to codon 29 - 356. 
These results suggest that the analysed p53 ORF fragment did not show any mutation, 
neither in healthy skin nor in lesion 3. 
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Figure 5: Agarose gel analysis of the PCR product 
     M: 1kb DNA ladder; p53_1: healthy skin, p53_2: lesion 3 
 
4.2 Cloning of CPV3 E6 into an amplicon destination vector 
In order to construct a Herpesvirus amplicon vector containing the CPV3 E6 open reading 
frame (ORF), the sequence corresponding to the E6 ORF was amplified by PCR and 
cloned into pENTR/D-TOPO vector as described in material and methods. 
Agarose gel analysis of the PCR product revealed a band of the expected size (450 bp) 
corresponding to the E6 ORF (Figure 2a). The isolated and purified PCR product was 
used for the TOPO cloning reaction. To identify clones containing the desired E6 ORF, 10 
colonies were picked, plasmid DNA isolated and restriction analysis with two restriction 
enzymes (AvaI and MluI) was performed. Five of the ten isolated clones showed the 
calculated restriction pattern. Figure 2b shows the agarose gel analysis of the five positive 
clones. To confirm that the E6 ORF was cloned in the proper orientation and contained the 
correct nucleic acid sequence, two clones showing the calculated restriction pattern were 
sequenced (pENTR-E6_B and pENTR-E6_C). By performing a Gateway LR 
recombination reaction between the pENTR-E6_B and an amplicon destination vector, 
containing the EYFP gene in frame with the recombination cassette RFC C.1 (pHSV-
EYFP-RfC), an expression clone containing the desired E6 ORF was generated (pHSV-
E6-EYFP). The resulting recombination reaction was again transformed into E.coli. 
Plasmid DNA was isolated from 6 colonies and restriction analysis with three restriction 
enzymes (NotI, ApoI and BlpI) was performed to confirm the presence of the insert. All the 
isolated expression clones showed the calculated restriction pattern. Figure 2c shows the 
 M         p53_1   p53_2 
506 
1018 
1636 
2036 
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restriction pattern of two expression clones (pHSV-E6-EYFP_K and pHSV-E6-EYFP_L). 
Sequence analysis confirmed that these two expression clones contained the E6 ORF in 
frame with EYFP. These results suggest that an amplicon expression clone containing the 
E6 ORF in frame with EYFP had been generated. 
 
 
Figure 2a: Agarose gel analysis of the PCR product 
M: 100bp DNA ladder; E6: PCR product 
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Figure 2b: Restriction analysis of the entry clone pENTR-E6 on agarose gel 
Left panel: virtual digestion: 
Lane 1: AvaI digestion of pENTR/D-TOPO: calculated fragment: 2580bp  
Lane 2: MluI digestion of pENTR/D-TOPO: calculated fragments: 1649bp, 931bp 
Lane 3: AvaI digestion of pENTR-E6: calculated fragments: 2600bp, 433bp 
Lane 4: MluI digestion of pENTR-E6: calculated fragments: 2102bp, 931bp 
Right panel: digestion of pENTR-E6: 
M: 1kb DNA ladder; A, B, C, D, G: clone A, B, C, D, G; a: AvaI digestion; b: MluI digestion.  
The arrow indicates the position of the 433bp fragment that was only faintly visible 
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Figure 2c: Restriction analysis of the amplicon expression clone pENTR-E6-EYFP on agarose gel 
Left panel: virtual digestion: 
Lane 1: NotI digestion of pHSV-EYFP-RfC: calculated fragments: 4952bp, 2323bp 
Lane 2: ApoI digestion of pHSV-EYFP-RfC: calculated fragments: 4889bp, 2016bp, 370bp 
Lane 3: BlpI digestion of pHSV-EYFP-RfC: calculated fragment: 7275bp 
Lane 4: NotI digestion of pHSV-E6-EYFP: calculated fragments: 4855bp, 1255bp 
Lane 5: ApoI digestion of pHSV-E6-EYFP: calculated fragments: 5740bp, 370bp 
Lane 6: BlpI digestion of pHSV-E6-EYFP: calculated fragments: 4942bp, 1168bp 
Right panel: digestion of pHSV-E6-EYFP: 
M: 1kb DNA ladder; K, L: clone K, L 
 
4.3 Quantitative PCR analysis 
To characterize the state of infection, the existence of CPV3 E6 mRNA in skin lesions and 
in healthy skin of the affected dog was determined. Glycerinaldehyd-3-phosphat-
dehydrogenase (GAPDH) mRNA was used as reference. 
4.3.1 Establishment of a real time PCR for CPV3 E6 
In order to facilitate measurement of CPV3 E6 and GAPDH mRNA levels, quantitative 
PCR-assays for CPV3 E6 and canine GAPDH DNA level were established first. Standard 
curves of two plasmids containing CPV3 E6 DNA (pHSV-E6-EYFP) and canine GAPDH 
(pTOPO-GAPDH) in a known concentration were created from a 10-fold serial dilution 
(from 106 to 103 copies/ reaction) and used for absolute quantification of DNA. Figure 6 
shows these standardcurves with a slope of –3.295 and a correlations coefficient of 0.985 
(pTOPO-GAPDH) and a slope of –4.033 and a correlations coefficient of 0.980 (pHSV-E6-
EYFP). Thus, these standardcurves could be used for the measurement and the absolute 
quantification of cDNA obtained by reverse transcription of RNA samples. 
  M    K     L    K    L     K    L    M 
NotI ApoI BlpI 
5090 
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Figure 6: Standardcurves of pTOPO-GAPDH (a) and pHSV-E6-EYFP (b) created from a 10-fold serial 
dilutions from 106 to 103 copies/ reaction. 
 
4.3.2 Detection of CPV3 E6 mRNA in several skin lesions 
In order to evaluate the presence of CPV3 E6-mRNA in the skin lesions of the affected 
dog, RNA was extracted from three different lesions and from macroscopically normal-
appearing skin and reverse transcribed. Since the E6 specific primer pair used was not 
able to distinguish between genomic viral DNA and reverse transcribed cDNA, mRNA-
samples analysed as negative controls, were treated in exactly the same way but the 
reverse transcriptase was substituted by water (no-RT samples). After reverse 
transcription quantitative real-time PCR was carried out. The Ct values from skin samples 
were used in combination with the standard curves of pTOPO-GAPDH and pHSV-E6-
EYFP to calculate the copy numbers of E6 and GAPDH mRNA. To avoid amplification 
from genomic DNA, several dilutions of cDNA extracts were analysed. The dilution, which 
gave no signal in the absence of reverse transcriptase was chosen for measuring E6 
mRNA levels. The difference in the Ct value was about +3.3 per 1:10 dilution, which is the 
value of optimal doubling of DNA amount per cycle. Since the amount of used RNA 
sample was not standardised, we compared different sample dilutions of the cDNA 
extracts. Figure 7 shows the dilution of different samples, which resulted in a GAPDH 
mRNA content between 103 and 104 copies. Therefore, the presented dilutions are 1:10 for 
healthy skin and lesion 1, 1:100 for lesion 2 and 1:1000 for lesion 3a and 3b. Every sample 
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was analysed at least two times. Table 3 shows the calculated copy numbers of E6 and 
GAPDH mRNA corresponding to Figure 7. E6 cDNA measurement of the 1:1000 dilution 
of lesion 3b revealed a positive Ct value of the no-RT sample, whereas the no-RT sample 
of the 1:10.000 dilution was negative. In this case we analysed the copy number of the 
1:10.000 dilution and calculated the corresponding copy number of the 1:1000 dilution. 
The remaining no-RT samples of the dilutions used in Figure 7 were negative. Thus CPV3 
E6 mRNA expression in the skin lesions of the affected dog was demonstrated, whereas it 
was not possible to detect any CPV3 E6 mRNA expression in healthy skin. The amount of 
E6 mRNA was slightly increased compared to the amount of GAPDH mRNA in the same 
extract. 
 
 
Figure 7: Results of the real time PCR: Y axis shows the copy number and X axis shows the different skin 
samples. Lesion 3a and 3b means it is the same lesion, but cut into two pieces. The number of circles/ 
triangles stands for the analysing frequency of each sample. CPV3-E6 mRNA was found in every lesion but 
not in healthy skin. The amount of E6 mRNA was slightly increased compared to the amount of GAPDH 
mRNA in the same extract. Although the amount of GAPDH of healthy skin is quite similar to the amount of 
GAPDH in lesions, E6 was not detectable in healthy skin. 
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Samples E6 GAPDH Samples E6 GAPDH 
Healthy skin 0 2147 Lesion 2 5572 3033 
Healthy skin 0 2466 Lesion 2 7808 4587 
Healthy skin 0 2302 Lesion 2 3554 3730 
Healthy skin 0 3250 Lesion 2 3359 4915 
Lesion 1 4980 541 Lesion 2 6596 _ 
Lesion 1 6236 939 Lesion 2 11574 _ 
Lesion 3a 3977 2149 Lesion 2 6978 _ 
Lesion 3a 3977 2149 Lesion 2 9243 _ 
Lesion 3b 2830 1522    
Lesion 3b 3350 2148    
 
Table 3: calculated copy number of E6 and GAPDH in the different samples. The equation of the linear 
regression describing the relationship between Ct-values and copy numbers of the plasmid was used for the 
calculation. 
 
4.4 Characterization of CPV3 E6-fusion protein in eukaryotic cell 
cultures 
4.4.1 Transfection of VERO cells with the pHSV-E6-EYFP amplicon vector 
In order to observe the expression and compartmentalization of the CPV3 E6 gene protein 
product in eukaryotic cells, VERO cells were transfected with pHSV-E6-EYFP_L. The cells 
were observed 24 and 48 hours post transfection under a fluorescence microscope. One 
day post transfection about five percent of the transfected cells showed yellow 
fluorescence, corresponding to the E6-EYFP fusion protein. This observation indicated, 
that E6-EYFP protein was expressed. Fluorescence seemed to be detectable only in the 
nuclei of positive cells. Observation of the cells by light microscopy revealed a star-like 
appearance implying a healthy state of the cells 24 hours post transfection. In order to 
verify the localization in the nucleus, nuclei were stained with Hoechst after 48 hours. An 
overlay of the pictures taken with YFP filter (Figure 3a), with DAPI filter (Figure 3b) and 
with normal light (Figure 3c) revealed that yellow fluorescence was accumulated 
exclusively in the nuclei (Figure 3d). At that time the cell profile of fluorescent positive cells 
by normal light microscopy was round shaped implying the cell to be dying (Figure 3c). 
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Figure 3: Vero cells 48 hours post transfection with pHSV-E6-EYFP: Cells were observed with a 40x 
objective in an inverse microscope using an UV filter for visualization of the fluorescence. Yellow 
fluorescence: E6-EYFP, blue fluorescence: nuclei stained with Hoechst. Cells were observed a) using the 
YFP filter b) using the DAPI filter c) with normal light and d) Overlay of pictures a, b and c: yellow 
fluorescence was accumulated exclusively in the nucleus of the transfected cells. 
 
4.4.2 Transduction of VERO/ VERO 2-2 cells with pHSV-E6-EYFP amplicon 
particles 
In order to achieve expression of the CPV3 E6 gene protein product under more gentle 
conditions, pHSV-E6-EYFP was packaged into HSV-1 particles. Therefore, Vero 2-2 cells 
were co-transfected with pHSV-E6-EYFP_L, a replication-competent, packaging-defective 
HSV-1 helper genome (fHSV∆pac∆27) and an additional helper plasmid (pEBHICP27). 
The cells were observed 24 and 72 hours post transfection. After 24 hours about fifty 
percent of the transfected cells showed yellow fluorescence, corresponding to the E6-
EYFP fusion protein. The amount of fluorescent cells as well as the intensity of 
fluorescence was higher than in absence of HSV-1, indicating that pHSV-E6-EYFP was 
augmented. Interestingly the amount of fluorescent cells was reduced after 72 hours. At 
that time amplicon particles were harvested. These amplicon particles were used to 
transduce VERO cells. After 24 hours cells were fixed on cover slips with 3% 
Paraformaldehyde and stained with DAPI. Figure 4 shows VERO cells one day post 
transduction with E6-amplicon particles. Again fluorescence, corresponding to the E6-
EYFP protein was detected in the nucleus of the transduced cells.  
 
a 
d 
b c 
 29 
 
Figure 4: Vero cells 24 hours post transduction with E6-EYFP amplicon virions: Cells were observed 
with a 40x objective in an inverse microscope using an UV filter for visualization of the fluorescence. Yellow 
fluorescence: E6-EYFP, blue fluorescence: nuclei stained with Dapi. Cells were observed a) using the YFP 
filter and b) using the Dapi filter. c) Overlay of pictures a and b. Fluorescence was accumulated in the 
nucleus of the infected cells.  
 
 
In a second experiment VERO 2-2 cells were transduced with these amplicon particles 
and observed 24, 48 and 72 hours post transduction. To avoid alterations of the cells with 
ultra violet light during observation, cells in three different wells were transduced. 
Observation was carried out after 24 hours in well 1, after 48 hours in well 2 and after 72 
hours in well 3. As a control VERO 2-2 cells were transduced with EYFP amplicon 
particles which were packaged at the same time with equal conditions. One day post 
transduction about five percent of the transduced cells showed yellow fluorescence, 
corresponding to the E6-EYFP fusion protein (Figure 5a). Observation of the cells by light 
microscopy revealed a star-like appearance implying a healthy state of the cells (Figure 
5b). Two days post transduction fluorescence agglutinated in the nucleus (Figure 5c). The 
cell profile of fluorescent cells by normal light microscopy was shortened implying the cell 
to be dying (Figure 5d). On day three post transduction fluorescent particles were 
swimming over the cell layer (Figure 5e). Observation of the cells by light microscopy 
revealed that cells corresponding to the fluorescent particles were round and detached 
from the monolayer cell culture implying a dead state of the fluorescent cells (Figure 5f). In 
contrast the cell profile of VERO 2-2 cells transduced with EYFP amplicon particles 
observed by light microscopy was star-like shaped on day one, two and three after 
transduction (Figure 5h). Thus, transduction of eukaryotic cells with pHSV-E6-EYFP 
amplicon particles resulted in two different observations. First, the E6-EYFP fusion protein 
was shown to localize exclusively in the nucleus. And second, transduction of pHSV-E6-
EYFP amplicon particles resulted in the death of cells after 72h.  
 
 
a b c 
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Figure 5: VERO 2-2 cells 24 (a, b), 48 (b, c) and 72 (e, f, g, h) hours post transduction with E6-EYFP 
amplicon virions (a-f) respectively EYFP amplicon virions (g-h): Cells were observed with a 40x 
objective in an inverse microscope using an YFP filter for visualization of the fluorescence. Yellow 
fluorescence: E6-EYFP (a, c, e) EYFP (g). Cells were observed a, c, e, g: using the YFP filter b, d, f, h: with 
normal light.  
 
4.5 Expression of HSV-1 Amplicon-encoded siRNAs 
4.5.1 Generation and packaging of siRNAs 
In order to construct a siRNA targeting CPV3 E6 mRNA, DNA oligonucleotides targeting 
E6 at two different locations were synthesized as 64-mer sense and antisense 
oligonucleotide templates and inserted into an amplicon vector (pHSVsuper) between the 
a b 
c 
e 
d 
f 
h g 
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BglII and the HindIII sites (pHSVsiE6-2 and pHSVsiE6-3) as describrd in Materials and 
Methods. To identify clones containing the desired DNA oligonucleotides, twelve colonies 
per plasmid were picked. Plasmid DNA was isolated and restriction analysis with two 
restriction enzymes (EcoRI and HindIII) was performed. Six (pHSVsiE6-2) respectively 
eight (pHSVsiE6-3) of the twelve isolated clones showed the calculated restriction pattern. 
Amplicon packaging and titration was performed as described in material and methods. 
Titration revealed titers of 2.72 x 107 TU/ml for pHSVsiE6-3, 2.66 x 107 TU/ml for 
pHSVsiEGFP and 2 x 107 TU/ml for pHSVsuper. Packaging of pHSVsiE6-2 was not 
successful.  
4.5.2 Conversion of the amplicon vector pHSV-E6-EYFP into pHSV-E6-mRFP 
To differentiate the expression of CPV3 E6 protein from the expression of the siRNAs, it 
was necessary to change the fluorescent protein of pHSV-E6-EYFP. Therefore pHSV-E6-
EYFP was digested with Asp718 and EcoRI to remove the EYFP and pcDNA-mRFP1-N 
was digested with the same enzymes to isolate the mRFP ORF. pHSV-E6 was ligated with 
the linearized mRFP. This ligation reaction was transformed into E.coli. Plasmid DNA was 
isolated from 12 colonies and restriction analysis with BamHI was performed to confirm the 
presence of the insert. Nine of the isolated expression clones showed the calculated 
restriction pattern. To confirm that the EYFP was replaced by mRFP, restriction analysis of 
two clones showing the calculated restriction pattern (pHSV-E6-mRFP_2 and pHSV-E6-
mRFP_4) with two more restriction enzymes (AvaI and MluI) was performed. As shown in 
figure 8 both clones showed the calculated restriction pattern. These results suggest that 
the fused fluorescent protein EYFP of pHSV-E6-EYFP had been replaced by mRFP.  
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Figure 8: Restriction analysis of the amplicon expression clone pENTR-E6-mRFP on agarose gel 
Left panel: virtual digestion: 
Lane 1: BamHI digestion of pHSV-E6-EYFP: calculated fragment: 6110bp 
Lane 2: PstI digestion of pHSV-E6-EYFP: calculated fragments: 2738bp, 2576bp, 796bp 
Lane 3: AatII digestion of pHSV-E6-EYFP: calculated fragment: 6110bp 
Lane 4: BamHI digestion of pHSV-E6-mRFP: calculated fragments: 5485bp, 570bp 
Lane 5: PstI digestion of pHSV-E6-mRFP: calculated fragments: 2576bp, 2548 bp, 931bp 
Lane 6: AatII digestion of pHSV-E6-mRFP: calculated fragments: 3864bp, 2191bp 
Right panel: digestion of pHSV-E6-mRFP: 
M: 1kb DNA ladder; 2, 4: clone 2, 4 
 
4.5.3 Transfection of siRNA infected VERO 2-2 cells with pHSV-E6-mRFP 
In order to block E6 protein expression in eukaryotic cells, VERO 2-2 cells were 
transduced with pHSVsiE6-3 with a multiplicity of infection (m.o.i.) of one respectively five 
TU per cell on day one. Amplicons that contained DNA oligonucleotides targeting EGFP 
(pHSVsiEGFP) and pHSVsuper were used as controls. On day two these cells were 
transfected with pHSV-E6-mRFP. Cells were observed on day two, three, four and five 
using a fluorescent microscope, which allows co-detection of both EGFP (green, amplicon-
transduced cells) and mRFP-E6 (red, transfected cells). One day after transduction about 
75% of the cells showed green fluorescence indicating, that the amplicon DNA had 
entered these cells and, thus siRNA was expressed. One day after transfection with 
pHSV-E6-mRFP about 5% of the cells showed red fluorescence indicating that the E6 
fusion protein was expressed. About 50% of the red cells showed coexistent green 
M     2      4     2      4     2     4 
BamHI PstI AatII 
506 
1018 
2036 
3054 
6108 
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fluorescence. No cells with bright green fluorescence and coexistent red fluorescence 
could be detected. These observations could be made in cells transduced with pHSVsiE6-
3 as well as in cells transduced with control amplicons pHSVsiEGFP and pHSVsuper 
(Figure 9a). Observations on day four were quite similar, whereas on day five cells 
expressing the red fluorescence looked round and dead while cells expressig only the 
green fluorescence had a star-like appearance implying a healthy state. Again this could 
be observed in cells transduced with pHSVsiE6-3 as well as in cells transduced with 
pHSVsiEGFP and pHSVsuper (Figure 9b). Thus no obvious reduction of red fluorescence 
(mRFP-E6) could be detected in cells treated with E6-specific siRNA (pHSVsiE6-3) 
compared to cells treated with control amplicons (pHSVsiEGFP and pHSVsuper). 
The purpose of the experiment was to evaluate a reduction of CPV3 E6 after incubating 
the cells with siRNA targeting CPV3 E6 (pHSVsiE6-3). For further control a vector without 
siRNA (pHSVsuper) and another vector with siRNA targeting EGFP (pHSVsiEGFP) was 
used. As expected in cells transduced with pHSVsuper no effect was observed four days 
after transduction. In cells transduced with pHSVsiEGFP no reduction of green 
fluorescence and in cells transduced with pHSVsiE6-3 no reduction of red fluorescence 
were recognized four days after transduction. It is known from the literature that the effect 
of eliminating green fluorescence by pHSVsiEGFP was observed seven days after 
transduction.45 Observation of cells seven days after transduction was not possible, 
because cells died three days after transfection with pHSV-E6-mRFP. 
 
 
 
 
 
 
 34 
 
Figure 9a: VERO 2-2 cells 48 hours post transduction with pHSVsiE6-3 (a-c), pHSVsiEGFP (d-f) and 
24 hours post transfection with pHSV-E6-mRFP: Cells were observed with a 40x objective in an inverse 
microscope using an UV filter for visualization of the fluorescence. Green fluorescence: GFP, red 
fluorescence: E6-mRFP. Cells were observed a and d: using the dsRed filter, b and e: using the GFP filter 
and c and f: with normal light. Red and green fluorescence in the same cell could be detected in pHSVsiE6-
3 as well as in pHSVsiEGFP infected cells.  
 
 
 
 
a 
d 
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Figure 9b: VERO 2-2 cells 4 days post transduction with pHSVsiE6-3 (a-c), pHSVsiEGFP (d-f), vector 
without siRNA (g-i) and 3 days post transfection with pHSV-E6-mRFP: Cells were observed with a 40x 
objective in an inverse microscope using an UV filter for visualization of the fluorescence. Green 
fluorescence: GFP, red fluorescence: E6-mRFP. Cells were observed a, d, g: using the dsRed filter, b, e, h: 
using the GFP filter and c, f, i: with normal light.  
 
 
 
 
 
 
 
 
a 
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5 Discussion 
Recently, we reported the cloning and sequencing of a novel canine PV genome (CPV3), 
isolated from a SCC of a dog with EV like skin lesions.5 The present work further analyses 
the role of CPV3 in the development of these lesions. In order to exclude other causative 
factors the p53 mRNA was sequenced and tested negative for mutations. Quantification of 
viral gene expression was achieved by evaluating the presence of CPV3 E6-mRNA in 
lesional and healthy skin. Presumably CPV3 plays an important role in the initiation of skin 
cancerogenesis as CPV3-E6 mRNA was detected in three different skin lesions, but not in 
healthy skin. To further characterize the putative transforming protein CPV3 E6 the 
expression and localization of the CPV3 protein in eukaryotic cells and effects of a siRNA 
targeting the CPV3 E6 gene on the E6 protein expression in cell cultures have been 
examined. 
 
Numerous studies suggest that UVR plays an important role in skin cancerogenesis.15,19 
This seemed to be unlikely in our case, because the SCC developed interdigitally, a place 
which is not reached by much UVR. Nevertheless, to eliminate the possibility of an UVR 
induced mutation of the p53 gene we analysed the nucleotide sequence of a large 
fragment of the p53 cDNA, isolated from healthy and lesional skin of the affected dog. 
Comparing the sequence with the canine p53 sequence, published by Setoguchi et al., 
revealed an identical sequence.50 Setoguchi found a DNA polymorphism in canine p53 at 
codon 325 (CTC or CGC). We found a G in all of the four sequenced clones at nucleotide 
974, thus codon 325 represented the CGC type. In human tumors mutational hot spots 
have been identified in the p53 gene. They are localized at codons 175, 245, 248, 249 and 
273.51 There are several reports on mutational analyses of the p53 gene in tumors of dogs, 
but most of them concentrated on regions known to contain the majority of missense 
mutations in human tumors. Setoguchi et al. were the first, who examined the entire ORF 
of the p53 cDNA of various tumors in dogs and they found a higher frequency of p53 
mutations, whereas only few were located at human mutational hot spots. They revealed 
30 different mutation sites from codon 28 to codon 376. Therefore, it seems to be rational 
to analyse the entire ORF and to find specific canine p53 mutational hot spots rather than 
to extrapolate them from human p53 to canine p53 sequence. Our shortened sequence 
covered 29 of these 30 mutations sites reported by Setoguchi. The mutation site at codon 
376, presenting a silent mutation, was missing. Sequencing two different clones of the p53 
 37 
cDNA derived from healthy as well as from lesional skin of resulted in the same p53 
sequence as published before. Hence, a mutation of the p53 gene in these skin lesions is 
most unlikely. Furthermore an immunsuppression of this dog due to other diseases or 
immunosuppressive treatment was excluded. Thus, CPV3 as a causative agent in the 
development of these skin lesions seemed to be evident. 
Real-time PCR analysis of skin samples of the affected dog revealed the presence of 
CPV3 E6-mRNA in all three lesions which were subject of the assay. Although the amount 
of GAPDH of healthy skin was in a similar range as in lesions, healthy skin did not contain 
any detectable CPV3 E6-mRNA. In lesion 1, it was even possible to demonstrate E6 
mRNA, although this sample contained less GAPDH mRNA compared to healthy skin 
(Figure 7). The detection of E6 mRNA exclusively in lesional skin indicated a relationship 
between CPV3 in the development of skin lesions. But whether or not CPV3 was able to 
induce cancer transformation and whether the virus was indeed the causative agent for the 
lesions remained not proven.  
The E6 gene was heterologously expressed by transfection of plasmids and transduction 
of amplicons. Observation of the intracellular localization of the CPV E6 protein showed an 
accumulation in dot-like structures within the nucleus. Guccione et al. reported differences 
in the cellular localization of low- and high-risk HPV E6 proteins. They found, the low risk 
HPV-11 E6 protein to be localized in the nucleus, whereas the high risk HPV-16 E6 protein 
was distributed throughout the cell. Furthermore they demonstrated that HPV-11 E6 
proteins accumulated in promyelocytic leukaemia (PML) bodies, also known as the PML 
oncogenic domains (PODs) but the HPV-16 E6 proteins did not.52 The Transcription of the 
E6E7 cassette of high risk HPVs yields full-length mRNA as well as two spliced products: 
E6*IE7 and E6*IIE7. Vaeteewoottacharn et al. determined the cellular distribution of the 
HPV 16 E6 wildtype protein, the E6*IE7 protein and an E6 splice donor mutant (E6MT) 
protein. They concluded, that the wild type E6 construct, which yields both full-length E6 
and E6*I proteins, and the E6*I construct were expressed throughout the cells, whereas 
the E6MT construct was primarily expressed in the nucleus.53 Taking these results into 
consideration with our observation that CPV3 E6 is exclusively expressed in the nucleus, it 
could be presumed, that the CPV3 E6 gene is not spliced and resemble therefore the HPV 
low-risk E6 proteins. In contrast, Tao et al. demonstrated that high-risk full-length E6 
proteins are distributed predominantly in the nucleus, whereas low-risk full-length E6 
proteins are localized in the cytoplasm.54 However, varying protein concentrations could 
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explain different protein distributions throughout the cell. Thus it is difficult to predict an 
oncogenic potential of a PV just because of the localization of its E6 protein. 
Expression of CPV3 E6 protein in eukaryotic cells resulted in a cell shortening and round 
appearance implying apoptosis. Thus transfection as well as transduction of CPV3 E6 
gene resulted in cell death. This result was in contrast to the expected function of the E6 
protein, which was predicted to prevent apoptosis. A possible explanation for this 
observation would be that immortalization can only be obtained by a joint function of E6 
and E7. Zur Hausen reviewed that indeed immortalization of various human cells can be 
achieved with either E6 or E7 genes of high risk HPVs and even more efficiently by their 
combined function.35 Several reports support the concept, that neither the individual genes 
E6 and E7 nor their cooperation is sufficient to convert normal cells into an immortalized or 
malignant state.35 However, it is yet unexplained why the introduction of CPV3 E6 resulted 
in cell death. An explanation would be either CPV3 E6 itself had detrimental properties or 
another condition, for example the fusion to EYFP, resulted in a noxious effect. In 
transfected cells, the act of transfection would possibly be noxious and cause cell death.  
Transduction with purified amplicon particles revealed no protein expression. A detrimental 
biological activity of the CPV3 E6 protein either destroying the cells themselves or 
interfering with the HSV-1 function could explain this finding. Thus non-purified amplicon 
particles with much “foreign material” (consisting of cell debris) were used to transduce 
cells with E6. This amount of “foreign material” could be responsible for the resulting cell 
death. But in contrast transduction with control EYFP amplicon particles, which were 
treated in exactly the same way revealed not the same cell pattern. Thus a putative 
noxious action of the protein itself can be supposed. This potentially damaging effect of 
CPV3 E6 could also be responsible for the relatively low titers resulting of packaging of 
this gene. However, further studies are necessary to either confirm or disprove these 
interpretations. 
Another approach would be to combine the findings of E6 accumulation in dot-like 
structures within the nucleus and cells death. If the dot-like structures represent PODs and 
the cell dies of apoptosis, the question about a connection between these conditions arise. 
Although the molecular function of PODs is currently not clear, there is accumulating 
evidence that they represent regulatory domains involved in various biological processes, 
including amongst others an apoptotic process.55 Guo et al. reported about an interaction 
and co-localization of the PML and the p53 protein in PODs and defined a PML-
dependent, p53-regulatory pathway for apoptosis.56 There are two principle apoptotic 
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pathways, (1) the intrinsic, mitochondria regulated pathway and (2) the extrinsic pathway, 
divided in a receptor-induced pathway and a nuclear apoptotic pathway. At this point of the 
study it would go to far to predict an apoptotic pathway, possibly affected by CPV3 E6. 
There are few arguments for the nuclear apoptotic pathway, maybe due to regulation of 
p53 ubiquitination. Further studies are necessary to determine, whether CPV3 E6 can 
interfere with an apoptotic pathway and if yes with which one. 
Treatment of cells with a siRNA targeting CPV3 E6 did not result in decreased expression 
of the E6 protein. We suggest several possible interpretations for this observation. First 
and foremost the use of a single siRNA targeting only one sequence of the CPV3 E6 gene 
is probably not sufficient. Reynolds et al. investigated the performance and the widely 
varying silencing abilities of 180 siRNAs targeting the mRNA of two genes.57 We designed 
a siRNA which targets the coding region of E6 predicted on the base of multiple sequence 
alignments to various PV E6 amino acid sequences. However, we cannot exclude that a 
sequence was targeted, whose blocking did not result in the desired effect. A broader 
approach for targeting several sites on the CDS of E6 was not possible due to time 
limitations. Three main concerns have to be taken into account for the consideration of our 
results. First, the fusion of E6 to mRFP resulted in a detrimental effect. Second, the 
amount of siRNA one day after transduction was not sufficient to inhibit the protein 
expression. And finally, due to transfection, the targeting mRNA existed in abundance and 
therefore difficult for the siRNA to work effectively. However, Saydam et al. reported the 
successful use of a siRNA under similar experimental conditions, in an experiment 
involving transduction of the siRNA 4 hours after transfection with the targeted gene.58  
 
Outlook: To define the role of CPV3 with regard to the aforementioned skin lesions, more 
details need to be known about the transforming properties not only of CPV3 E6, but also 
of CPV3 E7 and a combination of these two proteins. Therefore, further characterisation 
the CPV3 E7 protein and the effects of both putative transforming proteins E6 and E7 are 
necessary. To verify the hypothesis, that the CPV3 E6 protein induces cell death, it would 
be necessary to exclude the influence of the fluorescent fusion partner (EYFP or mRFP). 
Therefore, following approaches are necessary: 1) analysis of E6, which is not fused to 
EYFP or mRFP 2) analysis of E6, genetically fused to EYFP or mRFP sequences, but with 
the fusion partner in a separate reading frame to avoid its translation and 3) visualization 
of E6 by antibodies, either by anti-E6 antibodies or by taking advantage of a very small 
SV5-derived tag, against which antibodies are commercially available. To better imitate the 
 40 
natural host the use of canine kerationcytes cultures would be advantageous. In our RT-
PCR study it was difficult to fully eliminate the genomic DNA of CPV3. Thus it would be 
interesting to investigate the splicing pattern of CPV3 and construct mRNA specific 
primers facilitating the quantification of mRNA content in cell cultures. Finally, testing 
various siRNAs targeting CPV3 E6 and E7 in CPV3-positive cell lines, derived from a 
lesion of the affected dog would be of great interest, particularly to develop a causative 
therapy for this dog. 
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